<!DOCTYPE html>
<html lang="en">

<head>
  <title>Versea</title>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/3.4.1/css/bootstrap.min.css">
  <link rel="stylesheet" href="./css/index.css">
  <link rel="stylesheet" href="./css/font.css">
  <link rel="stylesheet" href="./css/about.css">
  <link rel="icon" type="image/png" href="./image/favicon-16x16.png" sizes="16x16">
  <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.4.1/jquery.min.js"></script>
  <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.4.1/js/bootstrap.min.js"></script>
</head>

<body>
  <div class="my-container container-fluid">
    <!-- Navbar menu -->
    <nav class="navbar navbar-default" id="header">
      <div class="container-fluid">
        <!-- Brand and toggle get grouped for better mobile display -->
        <div class="navbar-header">
          <button type="button" class="navbar-toggle collapsed" data-toggle="collapse"
                  data-target="#bs-example-navbar-collapse-1" aria-expanded="false">
            <span class="sr-only">Toggle navigation</span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </button>
          <a class="navbar-brand" href="/"></a>
        </div>

        <!-- Collect the nav links, forms, and other content for toggling -->
        <div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1">
          <ul class="nav navbar-nav navbar-right">
            <li>
              <a href="/about" class="active">
                <div class="menu-icon">
                  <img src="./image/mini_logo.png">
                </div>
                <div class="text">
                  About
                  <div class="line">&nbsp;</div>
                </div>
              </a>
            </li>
            <li>
              <a href="/clinic_development">
                <div class="menu-icon">
                  <img src="./image/mini_logo.png">
                </div>
                <div class="text">
                  Clinic Development
                  <div class="line">&nbsp;</div>
                </div>
              </a>
            </li>
            <li>
              <a href="/product" >
                <div class="menu-icon">
                  <img src="./image/mini_logo.png">
                </div>
                <div class="text">
                  HCP Products
                  <div class="line">&nbsp;</div>
                </div>
              </a>
            </li>
            <li>
              <a href="/partnership">
                <div class="menu-icon">
                  <img src="./image/mini_logo.png">
                </div>
                <div class="text">
                  PARTNERSHIPS
                  <div class="line">&nbsp;</div>
                </div>
              </a>
            </li>
            <li>
              <a href="/contact_us">
                <div class="menu-icon">
                  <img src="./image/mini_logo.png">
                </div>
                <div class="text">
                  Contact Us
                  <div class="line">&nbsp;</div>
                </div>
              </a>
            </li>
            <li>
              <a href="https://versea.com/?pg=profile" >
                <div class="menu-icon">
                  <img src="./image/mini_logo.png">
                </div>
                <div class="text last">
                  ORDER ONLINE
                  <div class="line">&nbsp;</div>
                </div>
              </a>
            </li>
          </ul>
        </div>
      </div>
    </nav>
    <!-- End Navbar menu -->

    <div class="about block-top height-block">
      <div class="row mr-0 ml-0 wrap-container">
        <div class="col-xs-12 col-sm-12 col-md-6 col-lg-6 lf lf-about info">
          <div class="col-12 title">
            <h1>about <span class="span-name">VERSÉA</span></h1>
          </div>
          <div class="col-12 text">
            Verséa Holdings is a US-based company with pharmaceutical, diagnostic,
            practice solutions and medical hemp divisions. Each division is focused
            on bringing innovative products and services that address unmet needs to the global medical marketplace.
          </div>
        </div>
        <div class="col-xs-12 col-sm-12 col-md-6 col-lg-6 rt image pr-0 pl-0">
          <img src="./image/about1.png" alt="about1"/>
        </div>
      </div>
      <div class="row mr-0 ml-0 wrap-container management-team">
        <div class="col-12 title team-header lf">
          <img src="./image/mini_logo.png">
          <h1 class="manage-title">Management Team</h1>
        </div>
      </div>
      <div class="block-management-team">
        <div class="row mr-0 ml-0 management-team-header">
          <div class="wrap-container">
            <div class="col-xs-12 col-sm-12 col-md-4 col-lg-4">
              <div class="col-12 title">
                <h3>Sean Fetcho</h3>
                <h4>Co-Founder, Chief Executive Officer</h4>
              </div>
            </div>
            <div class="col-xs-12 col-sm-12 col-md-4 col-lg-4">
              <div class="col-12 title">
                <h3>Steve Porada</h3>
                <h4>Co-Founder, Chief Operating Officer</h4>
              </div>
            </div>
            <div class="col-xs-12 col-sm-12 col-md-4 col-lg-4">
              <div class="col-12 title">
                <h3>Dr. Moeller-Bertram</h3>
                <h4>Co-Founder, Chief Medical Officer</h4>
              </div>
            </div>
          </div>
        </div>
        <div class="row mr-0 ml-0 management-team-content">
          <div class="wrap-container">
            <div class="col-xs-12 col-sm-12 col-md-4 col-lg-4">
              <div class="col-12 content">
                <p>Mr. Fetcho has been involved with early stage and start-up companies for the last 15 years.
                  He has been a co-founder in multiple companies, including a revolutionary packaging technology that sustains
                  the life of produce and flowers while in transit all while killing off food-borne pathogens.
                  Sean has worked alongside major politicians and leading sustainability organizations around
                  the world to develop strategies around fighting global hunger. In the healthcare industry, Sean successfully crested,
                  launched and oversaw a highly profitable set of print and digital publications, targeting oncology, pain management
                  and cardiology professionals. Most recently with PAINWeek, Sean developed new revenue streams that helped
                  structure the business for an exit. </p>
                <p>Within 3 years, PAINWeek sold to a public company traded on the London Stock Exchange. 
                  From this experience within the analgesics and co-morbidities in pain space,
                  he quickly realized the opioid epidemic is rapidly growing and that the world is seeking change.
                  He believed Alternative Therapy treatments will be the future and farm bill compliant hemp can be
                  one of these groundbreaking solutions. Versea was then conceptualized between the founders.
                  Sean attended University of Westminster and Towson University  with degrees in Economics & Psychology.
                  He participated in Columbia University's School of Business training programs for executives and advanced
                  training in Neuro-Linguistic Programming, Urgency-Based Selling, Strategic Intuition, Management, Sales and Business Development </p>
              </div>
            </div>
            <div class="col-xs-12 col-sm-12 col-md-4 col-lg-4">
              <div class="col-12 content">
                <p>Mr. Porada has over 30 years of pharmaceutical research and commercialization experience and is a co-founder of Verséa Holdings.
                  He began his career as a research scientist at Ciba-Geigy, now Novartis, and later held a variety of sales, marketing and commercialization
                  positions at pharmaceutical and medical device companies. In 2004 Stephen’s entrepreneurial experience began with joining Aventine Co,
                  a startup medical marketing and communications company focused in the therapeutic area of pain. Stephen, as partner, directly engaged with,
                  consulted on, and established a variety of commercial-related plans and strategies spanning 12 unique analgesic brands. His work included
                  preapproval clinical trial and market development plans, tactical new formulation development, multi-partner commercial planning, strategic marketing,
                  launch planning and implementation. In addition to his work related to product commercialization, Stephen conceptualized and founded Aventine’s primary
                  asset, PAINWeek, which was ultimately sold to Tarsus, a publicly traded company on the London Stock Exchange</p>
              </div>
            </div>
            <div class="col-xs-12 col-sm-12 col-md-4 col-lg-4">
              <div class="col-12 content">
                <p>Toby is also the Chief Medical Officer of Summit Institute and Desert Clinic Pain Institute that has 12 locations in Southern California.
                  Prior to going into private practice, he held an appointment as associate clinical professor of anesthesiology and psychiatry and as
                  the director of clinical pain research at the University of California San Diego. He is double-board certified in Anesthesiology and
                  Pain Management and became an assistant clinical professor and enrolled in the masters program for clinical research. He joined the
                  VA San Diego Healthcare System and established his pain clinic there serving the Veteran population. Dr. Toby also serves as the Director
                  of Research with Vitamed Research, LLC., conducting research projects and trials in the field of pain and neurosciences.
                  Dr. Toby served as the director for clinical pain research at UCSD, is well published and is an associate clinical professor (voluntary)
                  with the University of California Riverside School of Medicine</p>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div class="block-management-team">
        <div class="row mr-0 ml-0 management-team-header">
          <div class="wrap-container">
            <div class="col-xs-12 col-sm-12 col-md-6 col-lg-6">
              <div class="col-12 title">
                <h3>SGary Lewandowski</h3>
                <h4>Chief Marketing Officer</h4>
              </div>
            </div>
            <div class="col-xs-12 col-sm-12 col-md-6 col-lg-6">
              <div class="col-12 title">
                <h3>Joe Magnemi</h3>
                <h4>Chief Financial Officer</h4>
              </div>
            </div>
          </div>
        </div>
        <div class="row mr-0 ml-0 management-team-content">
          <div class="wrap-container">
            <div class="col-xs-12 col-sm-12 col-md-6 col-lg-6">
              <div class="col-12 content">
                <p>Gary has over 23 years of pharmaceutical commercialization experience.
                  He is the Founder and President of Sapient Pharmaceutical Advisors Inc., a consulting company
                  targeting startup companies preparing for commercialization. Prior to this Gary was the Senior
                  Director of Market Development at Depomed Pharmaceuticals and led the commercial development and
                  execution of strategy for a portfolio of Pain and CNS brands including Cambia®, Zipsor®, Gralise®,
                  Lazanda®, Nucynta®, Nucynta® ER and a new chemical entity cebranopadol. Gary was Senior Director of
                  Marketing and successfully led the re-launch of the $1 billion-dollar acquisition of the Nucynta and Nucynta ER franchise.
                  Prior to Depomed, Gary was Director of Marketing at Purdue Pharma L.P. overseeing the portfolio of pain products including
                  MS Contin®, MSIR®, OxyContin®, OxyFAST®, OxyIR®, Dilaudid®, Dilaudid® HP, Palladone®, Ryzolt®, Butrans®, and Hysingla® ER.
                  Gary is an experienced commercial leader who has overseen new product development ranging from Pre-clinical through Launch and Phase IV.</p>
              </div>
            </div>
            <div class="col-xs-12 col-sm-12 col-md-6 col-lg-6">
              <div class="col-12 content">
                <p>Joe is a Financial and Operations Executive with over 30 years of experience working primarily as a
                  Chief Financial Officer in the Healthcare Advertising space. Having worked for two of the largest
                  healthcare agencies in the world; Cline Davis & Mann and Grey Healthcare. These companies produce marketing
                  and sales promotion materials for some of the largest selling pharmaceutical drugs in the world like Lipitor,
                  Viagra and Chantix. Joe is an experienced manager for both large corporate environments as well as start-up ventures,
                  with proven success in the evaluation and negotiation of acquisitions and sales. He then entered the early stage company
                  world as the leader in fincnaical execution, management and capital raises. His expertise is in client relations and strategy,
                  financial, project management and business systems</p>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div class="block-management-team">
        <div class="row mr-0 ml-0 management-team-header">
          <div class="wrap-container">
            <div class="col-xs-12 col-sm-12 col-md-4 col-lg-4">
              <div class="col-12 title">
                <h3>Monil Shah, PharmD, MBA </h3>
                <h4>Head of Clinical Development</h4>
              </div>
            </div>
            <div class="col-xs-12 col-sm-12 col-md-4 col-lg-4">
              <div class="col-12 title">
                <h3>Carlos Alfaras</h3>
                <h4>Chief Strategy Officer</h4>
              </div>
            </div>
            <div class="col-xs-12 col-sm-12 col-md-4 col-lg-4">
              <div class="col-12 title">
                <h3>Tony Dicks</h3>
                <h4>Head of Sales & Customer Success</h4>
              </div>
            </div>
          </div>
        </div>
        <div class="row mr-0 ml-0 management-team-content">
          <div class="wrap-container">
            <div class="col-xs-12 col-sm-12 col-md-4 col-lg-4">
              <div class="col-12 content">
                <p>Senior, C-level executive with over 20 years of pharmaceutical and biotechnology industry experience in oncology, dermal, and pain drug
                  development. Dr. Shah is the Chief Development Officer at WindMIL Therapeutics and Clinical Development consultant at TKL Research working
                  on optimizing dermal and pain therapeutics. He was the Chief Operating Officer of IRX Therapeutics /Brooklyn ImmunoTherapeutics. Prior to
                  that, he was the Medical Affairs Lead for Immuno-Oncology at Bristol Myers Squibb. Dr. Shah was Head of Clinical Operations and Development
                  at Ventrus Biosciences working on their GI pain NCE/NME and 505(b)(2) portfolio prior to its merger with Assembly Biosciences. Prior to
                  Ventrus, Dr. Shah led the solid tumor development programs and led the clinical portfolio and strategic planning function at Celgene
                  Corporation. He led the Oncology Development and Operations activities at Fibrogen and Novacea. Dr. Shah began his career at Novartis in
                  the Oncology Early Development Group leading clinical trials prior to joining the Medical Sciences Group at Amgen. Dr. Shah received his
                  BS and PharmD degrees from Rutgers University in New Jersey and his MBA from Florida Institute of Technology</p>
              </div>
            </div>
            <div class="col-xs-12 col-sm-12 col-md-4 col-lg-4">
              <div class="col-12 content">
                <p>Mr Alfaras comes to Versea as a Proven Leader in Pharma, Biotech and Healthcare as a C-Suite Executive with a demonstrated history of success
                  and Skilled Leadership in Pharmaceutical, Biotechnology, Medical Device, Strategic Planning and Business Development. Carlos has served as
                  President & CEO of Gensco Pharma beginning January of 2011. Since the acquisition, the company has developed and launched five new products
                  based on Patented Transdermal drug delivery technology and increased market valuation to over $200MM under his direction. Carlos has been Head
                  of Business Development, Bioniche Pharma (Acquired by Mylan Specialty), Senior Director Alternate Care and Business Development,
                  ANDA Pharmaceuticals/ANDRX Corporation (Acquired by WATSON Pharmaceuticals), Executive Director, Head of Business Strategy and Global Development
                  ANDA/Watson Pharmaceuticals (Acquired by TEVA) . He attended the University of Miami, majoring in Biology/Pre-Medical studies and utilized this
                  education and experience to enter the pharmaceutical management world.  In his dedication for the pursuit of excellence, he has had successes in
                  creating growth in revenues at every company he has been associated with through education, team building, strategic planning and efficiently
                  determining the development strategies for all</p>
              </div>
            </div>
            <div class="col-xs-12 col-sm-12 col-md-4 col-lg-4">
              <div class="col-12 content">
                <p>Tony has 17-years of experience in the healthcare industry. He is a 10-year veteran of Eli Lilly with a proven track record of creating and
                  executing direct-to-physician campaigns that grow market share and profits. He has a broad range of functional experience, from leading
                  high-performance sales teams as a field-based sales rep and district sales manager, to improving sales effectiveness and efficiency as a
                  brand manager and LEAN Six Sigma Black Belt. As a member of the Verséa team, Tony is applying his unique mix of experience and expertise
                  to lead the demand generation segment of the marketing team: Creating sales messaging, training programs, and promotional campaigns to reach,
                  acquire, and retain doctors, nurses, hospitals and other healthcare professionals ("Customers") interested in purchasing Verséa products for
                  distribution to individual consumers. Tony got his B.S. in Marketing from North Carolina A&T State University and his MBA at Northwestern's
                  Kellogg School of Management where he majored in finance, marketing and organizational behavior</p>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div class="block-management-team">
        <div class="row mr-0 ml-0 management-team-header">
          <div class="wrap-container">
            <div class="col-xs-12 col-sm-12 col-md-6 col-lg-6">
              <div class="col-12 title">
                <h3 style="margin-top: 7px;">Kip Vought</h3>
                <h4>Pharmaceutical R&D/<br> Regulatory Affairs for Global Markets</h4>
              </div>
            </div>
            <div class="col-xs-12 col-sm-12 col-md-6 col-lg-6">
              <div class="col-12 title">
                <h3>Jinhui Dou, Ph.D. </h3>
                <h4>Regulatory/FDA Expert for Botanical Markets</h4>
              </div>
            </div>
          </div>
        </div>
        <div class="row mr-0 ml-0 management-team-content">
          <div class="wrap-container">
            <div class="col-xs-12 col-sm-12 col-md-6 col-lg-6">
              <div class="col-12 content">
                <p>Senior pharmaceutical R&D and regulatory executive with over 20 years of industry experience across major global markets
                  with an underlying philosophy that R&D supports commercial. Highly experienced in determining and executing efficient and
                  cost-effective global development program. Successful leadership in preparation and conduct of Agency meetings
                  (PIND and equivalent, EOP1, EOP2, and PNDA/MAA and regional equivalents) obtaining agreement on data requirements for
                  introducing pharmaceutical products to the clinic, progressing through development including conduct of pivotal studies,
                  and preparation/submission of market applications. Regulatory strategy development includes obtaining orphan drug status,
                  Fast Track status (and global equivalents), and accelerated approval for orphan indications and/or breakthrough therapies.
                  Successful leadership in the execution of development programs through preclinical development to market approvals, and supporting commercial
                  products (i.e., post-approval studies to support label changes, promotional materials, and CMC changes). Indications include oncology,
                  analgesia, dermatology, gastrointestinal, cardiovascular, anti-infectives, and pulmonary/respiratory.
                  Experience extends to NCE/NMEs, repurposed drugs (505(b)(2)/10(c) and equivalents), siRNAs, monoclonal antibodies,
                  oligonucleotides, biologics, high-value generics, and over-the-counter (OTC) products (including novel dosage forms).
                  Dosage forms include solid oral (including modified release), topical/transdermal (patches, creams, ointments, gels, etc.),
                  sprays (oral and topical), inhalation, nasal, and parenteral. Lead in technical due diligence in both in-licensing and out-licensing
                  business development, including M&A. Served as primary lead in technical due diligence on behalf of financial institutions (private equity, venture capital, investment banks)</p>
              </div>
            </div>
            <div class="col-xs-12 col-sm-12 col-md-6 col-lg-6">
              <div class="col-12 content">
                <p>After receiving his BS (Pharmacy) and MS (Pharmacognosy) degrees, Jinhui Dou became a faculty member at Beijing University of Chinese
                  Medicine and taught pharmacy classes for 4 years. He accepted a graduate assistantship from the Pharmacognosy Department at the University
                  of Mississippi and received a PhD degree in 1996 from Dr. James McChesney, a distinguished professor of pharmacognosy. After working at the
                  University of Kansas as a post-doc associate, he became a Natural Product Scientist at NaPro BioTherapeutics in December 1996. He led a group
                  of chemists and engineers in the reduction of paclitaxel manufacturing costs and in the establishment of a library of related-substance reference
                  standards to support the CMC, pharmacology, and toxicology sections of paclitaxel NDA and ANDA filings.  Dr. Dou joined the FDA in 2002 as a
                  pharmacologist reviewer in the Center for Drug Evaluation and Research (CDER).  He reviewed anti-infective and anti-inflammatory chemical-drug
                  filings for several years before working as a botanical reviewer full time.  He was a CDER and Agency expert pharmacologist and pharmacognosist
                  specialized in botanical drug review.  Dr. Dou received numerous awards from CDER, FDA, and HHS for his distinguished contributions to the
                  development of new drug guidances, policies, and regulations and his scientific reviews of new chemical and botanical drugs. After more than 15 years
                  at the FDA, he now works as a chief advisor with Verséa Pharmaceuticals and provides consultations on cannabis chemistry, nonclinical and clinical
                  development related projects for the clinical pathway and FDA advancements. Dr. Dou is a member of American Society of Pharmacognosy (ASP) and the
                  NIH/NCI PDQ Integrative, Alternative, and Complementary Therapies (IACT) editorial board.  His publications on anticancer, chemo-preventative, and
                  anti-infective drugs or bioactive natural products, including lupin alkaloids, green tea, quassinoinds, and proanthocyanidins, are from his academia
                  and industry research activities or FDA new drug review experience</p>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <!-- Footer -->
    <div class="footer">
      <div class="row">
        <div class="item-footer"><a href="#">Privacy Policy</a></div>
        <div class="item-footer"><a href="#">Cookie Policy</a></div>
        <div class="item-footer"><a href="#">Terms & Conditions</a></div>
        <div class="item-footer"><a href="#">Contact</a></div>
        <div class="item-footer"><a href="#">©2020 Versea. All Rights Reserved.</a></div>
        <div class="item-footer"><a href="#">IMPORTANT SAFETY INFO DOWNLOAD</a></div>
      </div>
    </div>
    <!-- End Footer -->
  </div>
  <script type="text/javascript" src="js/index.js"></script>
</body>

</html>